COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,846 Articles (22,553 medRxiv, 8,293 bioRxiv)

Most recent first Previous |  Page 757: Articles 7561-7570  | Next

SARS-CoV-2 variants do not evolve to promote further escape from MHC-I recognition
Moriyama, M., Lucas, C., Monteiro, V. S., Iwasaki, A.
10.1101/2022.05.04.490614 — Posted: 2022-05-04
Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta
Grint, D. J., Wing, K., Gibbs, H. P., Evans, S. J., Williamson, E. J., Bhaskaran, K., McDonald, H. I., Walker, A. J., Evans, D., Hickman, G., Mathur, R., Schultze, A., Rentsch, C. T., Tazare, J., Douglas, I. J., Curtis, H. J., Morton, C. E., Bacon, S. C., Davy, S., MacKenna, B., Inglesby, P., Croker, R., Parry, J., Hester, F., Harper, S., DeVito, N. J., Hulme, W. J., Bates, C., Cockburn, J., Mehrkar, A., Goldacre, B., Eggo, R. M., Tomlinson, L.
10.1101/2022.05.03.22274602 — Posted: 2022-05-03
Sensitivity of novel SARS-CoV-2 Omicron subvariants, BA.2.11, BA.2.12.1, BA.4 and BA.5 to therapeutic monoclonal antibodies
Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., Sato, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium
10.1101/2022.05.03.490409 — Posted: 2022-05-03
Spatiotemporal landscape of SARS-CoV-2 pulmonary infection reveals Slamf9+Spp1+ macrophages promoting viral clearance and inflammation resolution
Cong, B., Dong, X., Yang, Z., Yu, P., Chai, Y., Liu, J., Zhang, M., Zang, Y., Kang, J., Feng, Y., Liu, Y., Feng, W., Deng, W., Li, F., Yu, Q., Gu, Y., Li, Z., Liu, S., Xu, X., Zhong, N., Ren, X., Qin, C., Liu, L., Wang, J., Cao, X.
10.1101/2022.05.03.490381 — Posted: 2022-05-03
Protection from Omicron and other VOCs by Bivalent S-Trimer COVID-19 Vaccine
Su, D., Li, X., Huang, X., He, C., Zeng, C., Wang, Q., Mu, Z., Qin, W., Ambrosino, D., Siber, G., Clemens, R., Liang, J. G., Liang, P., Jackson, N., Xu, R.
10.1101/2022.05.03.490428 — Posted: 2022-05-03
Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients with Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study
Shehab, M., Alrashed, F., Alfadhli, A., Alsayegh, A., Aldallal, U., Cherian, P., Alkhairi, I., Thanaraj, T. A., Channanath, A., Dashti, A. A., Albanaw, A., Ali, H., Abu-Farha, M., Abubaker, J. T., Al-Mulla, F.
10.1101/2022.05.03.22274608 — Posted: 2022-05-03
Population-based Oral Cancer Service Screening Disrupted by COVID-19 Pandemic: Observational and Simulation Study
Su, C.-W., Liu, Y.-T., Yen, A. M.-F., Chiu, H.-M., Chen, T. H.-H., Hsu, T.-H., Shih, M.-Y., Su, W. W.-Y., Chen, S. L.-S.
10.1101/2022.05.03.22274618 — Posted: 2022-05-03
SARS-CoV-2 outbreaks in secondary school settings in the Netherlands during fall 2020; silent circulation
Jonker, L., Linde, K. J., de Hoog, M. L., Sprado, R., Huisman, R., Molenkamp, R., Oude Munnink, B. B., Dohmen, W., Heederik, D. J., Eggink, D., Welkers, M. R., Vennema, H., Koopmans, M. P., Fraaij, P. L., Wouters, I. M., Bruijning-Verhagen, P. C.
10.1101/2022.05.02.22273861 — Posted: 2022-05-03
Kidney Transplant Recipients and Omicron: Outcomes, effect of vaccines and the efficacy and safety of novel treatments
Gleeson, S., Martin, P., Thomson, T., Thind, A., Prendecki, M., Spensley, K. J., Clarke, C., Roufosse, C., Pickard, G., Thomas, D., McAdoo, S. P., Lightstone, L., Kelleher, P., Willicombe, M.
10.1101/2022.05.03.22274524 — Posted: 2022-05-03
An Early Return-to-Work Program for COVID-19 Close Contacts in Healthcare During the Omicron Wave in Japan
Naruse, H., Doi, Y., Iwata, M., Ishikawa, K.
10.1101/2022.05.02.22274478 — Posted: 2022-05-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).